Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental ...

SGLT2 inhibitors may improve glycaemic control and renal markers without affecting body weight in patients with Prader-Willi syndrome and T2D, but they are tied to an elevated risk for adverse events.

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Topline results were announced from a phase 3 trial investigating intranasal carbetocin for the treatment of hyperphagia in Prader-Willi syndrome.

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...

Prader-Willi syndrome is a genetic disorder caused by changes to chromosome 15. It affects growth, behavior, and learning and requires continual management to avoid potentially life threatening ...

Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 ...

Actor Colin Farrell recently disclosed that his son, James, has Angelman syndrome, one of the driving factors behind Farrell's support for finding a cure for Angelman syndrome and for launching the ...

Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. — -- Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. “Even if she's just eaten, we can … ...

Mothers are often encouraged to trust their instincts, especially regarding their children's health. But for Tiffany Young, getting others to take her concerns seriously proved challenging when her ...

Prader-Willi syndrome is a genetic disorder that affects growth, behavior, and learning. There is no cure for the syndrome, but continual monitoring and treatment may improve a person’s quality of ...